Medicare AdvantageCoverageMedium impact
MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Critical Care·Pharmacy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.016h regarding treatment of pulmonary artery hypertension with intravenous, subcutaneous, and inhaled pharmacologic agents has been reissued. This is a pharmacy-related policy update that may affect coverage and billing for specialized PAH treatments.
Action Required
By June 10, 2026: Billing team should review the complete policy document at the provided URL to understand specific changes to coverage criteria for pulmonary artery hypertension treatments. Update prior authorization procedures and billing protocols for IV, subcutaneous, and inhaled PAH medications for Medicare Advantage patients.